Michael R Hodges, Eric Ople, Pamela Wedel, Karen J Shaw, Abhijeet Jakate, William G Kramer, Sjoerd van Marle, Ewoud-Jan van Hoogdalem, Margaret Tawadrous
Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX, interferes with cell wall synthesis by targeting fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, thereby causing loss of cell viability. Data from two phase 1, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) studies evaluating safety, tolerability, and pharmacokinetics of FMGX (doses up to 1,000 mg, i...
March 29, 2023: Antimicrobial Agents and Chemotherapy